All In Biotech

NDA 012380 · Parke Davis

Zarontin

Ethosuximide · Oral · Anti-epileptic Agent

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1960

Nov 2, 1960

Approved uses

1

Original approval plus efficacy supplements

Registered trials

12

3 Phase 3, 2 recruiting

FAERS reports

2,522

2,030 serious, 64 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 25, 2026.

INDICATIONS AND USAGE Zarontin is indicated for the control of absence (petit mal) epilepsy.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 2, 1960 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • ZARONTIN · ETHOSUXIMIDE 250MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethosuximide" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective519
  • seizure375
  • off label use245
  • somnolence162
  • generalised tonic-clonic seizure153
  • treatment failure121
  • petit mal epilepsy120
  • drug interaction117
  • fatigue113
  • epilepsy108
  • condition aggravated107
  • multiple-drug resistance104

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200416
200537
200639
200739
200851
200935
201050
201151
201257
201358
201454
2015115
201692
2017106
2018135
2019186
2020175
2021225
2022234
2023215
2024194
2025251
2026107

Recalls

1 FDA enforcement reports for this application.

  • Sep 12, 2019 · Class III · Terminated

    Labeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zarontin (Ethosuximide)

2024 spending

$67K

Beneficiaries

62

298 claims

Per beneficiary

$1,080

$1.13 per unit

View as table
YearSpending
2020$424,674
2021$427,579
2022$393,866
2023$216,704
2024$66,933

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 68 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.